CURRICULUM VITAE
Binod Dhakal MD
Binod Dhakal MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Department of Medicine
Division of Hematology and Oncology - Medicine
OFFICE ADDRESS: |
Clinical Cancer Center |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
Fax: 414-955-0231 |
Email: bdhakal@mcw.edu |
EDUCATION: |
01/1999 - 09/2004 MBBS, Manipal College of Medical Sciences, Pokhara, Nepal |
07/2007 - 06/2010 M.D., Saint Francis Hospital, Evanston, IL |
07/2013 - 06/2016 Hematology/Oncology Fellow, Medical College of Wisconsin, Milwaukee, WI |
06/2015 - 04/2016 M.S., Clinical and Translational Institute of Southeast Wisconsin, Milwaukee, WI |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/2007 - 06/2010 Resident, Internal Medicine, Saint Francis Hospital, Affiliated to University of Illinois at Chicago, Chicago, IL |
07/2013 - 06/2016 Fellow, Medicine, Hematology/Oncology, Medical College of Wisconsin Affiliated Hospitals, 9200 W Wisconsin Ave, Milwaukee, WI WI |
FACULTY APPOINTMENTS: |
07/2010 - 06/2013 Assistant Professor of Medicine, General Internal Medicine, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI 53226 |
07/2016 - 12/2019 Assistant Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 |
01/2020 - Present Associate Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 |
HOSPITAL STAFF PRIVILEGES: |
07/2007 - 06/2010 Saint Francis Hospital, Affiliated to University of Illinois at Chicago, 355 Ridge Ave, Evanston, IL 60202 |
07/2010 - Present Medicine, Hematology and Oncology, Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226 |
06/2018 - Present Froedtert South Medical Center, Pleasant Prairie, WI 53158 |
11/2018 - Present VA Zablocki Medical Center, 5000 W National Avenue, Milwaukee, WI |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine | 08/2010 | 08/2020 |
Medical Oncology | 12/2016 | 12/2026 |
Hematology | 12/2016 | 12/2026 |
Licensure | Number | Issue Date | Expiration |
Illinois License | 036124054 | 07/2007 | 06/2010 |
Wisconsin License | 54325-20 | 08/2015 | 10/2025 |
AWARDS AND HONORS: |
01/1999 Ministry of Education Scholarship to study Medicine based on nationwide merit examination |
01/2003 Distinction in Basic Science |
07/2008 Third position in regional medical jeopardy, ACP |
10/2010 Nominated as the best teacher award for new faculty , Medical College of Wisconsin Internal medicine residency program |
06/2011 Outstanding Medical Student Teacher award |
04/2013 Best oral abstract award ($2500), Center Society of Clinical Research |
12/2013 Affiliated hospitals Research award, Medical College of Wisconsin |
06/2014 Travel Trainee Award, American Society of Oncology |
03/2015 Best Poster award, 1st Annual Department of Medicine Research Retreat, Medical College of Wisconsin |
06/2015 The Mazie Froedtert Willms and Sue Froedtert Cancer Fellowship |
07/2015 ASBMT Clinical Trials Workshop, American Society of Blood and Marrow Transplantation |
07/2015 Chief Fellow, Hematology/Oncology Medical College of Wisconsin Affiliated Hospitals |
06/2017 Outstanding Medical Student Teacher Award 2016 - 2017 |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Ad-Hoc Reviewer |
01/2009 - 01/2015 International Journal of User Driven Health Care |
01/2014 Associate Faculty Member, F1000 prime |
08/2014 BMJ case reports |
09/2015 Journal of Clinical Oncology |
06/2016 Biology of Blood and Marrow Transplantation |
07/2016 Blood Work |
11/2016 Bone Marrow Transplantation |
03/2017 Leukemia and Lymphoma |
10/2017 Journal of Clinical Apheresis |
12/2017 ASH News Daily (Editorial Board) |
03/2019 British Journal of Hematology |
07/2019 ASH News Daily (Editorial Board) |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
Dhakal, Binod, Sukumaran S, Haasler G, Tisol W, Gasparri M, Choong N, Surgery for Lung Cancer in Obese Patients; Is it Riskier?, World Lung Cancer, Amsterdam, 2011 |
National |
Chaudhuri S, Reddy R, Singh S, Dhakal B., Review of individual readmissions by hospitalist; Preliminary findings of quality improvement project, National SGIM, Philadelphia, 2011 |
Dhakal B., Cohen E, Hari P, Palmer J, Nephrotic Syndrome caused by graft vs. host disease-is it real?, CSCR meeting, Chicago, IL, 2013 |
Dhakal B, Hari P, Rein L, Fraser R and Padmanabhan A, Use of “Big Data” to Define Disease Burden, Complication Rates and Health Care Costs in Patients with Heparin Induced Thrombocytopenia (HIT), American Society of Hematology, San Diego, CA, 12/2016 |
Dhakal B, Giri S, Levin A, Rein L, Chhabra S, Shah N, Szabo A, D’Souza A, Pasquini M, Hari P and Hamadani M, Association between hospital volume and 30-day readmissions following allogeneic hematopoietic stem cell transplantation (HCT) in US, American Society of Hematology, San Diego, CA, 12/2018 |
Dhakal, Binod, Managing Early Relapse in Multiple Myeloma, American Society of Clinical Oncology, Chicago IL, 06/03/2019 |
Dhakal, Binod, Novel prognostic scoring system in multiple myeloma patients undergoing autologous stem cell transplantation, American Society of Hematology, Orlando , FL, 12/2019 |
Dhakal, Binod, TCEs and CARS- Selecting Right Patient at Right time, International Myeloma Society, Chicago, IL, 04/2022 |
Dhakal, Binod, Immunotherapy in Multiple Myeloma: Beyond CAR-T, 2nd Midwest Cellular Conference, 04/2022 |
Dhakal, Binod, Allogeneic CAR-T approaches in Multiple Myeloma, International Myeloma Society, Boston, MA, 05/2022 |
Dhakal, Binod, CAR-T vs. Bispecific antibodies in Multiple Myeloma, Updates in Cancer Novel Immunotherapies, Updates in Cancer Novel Immunotherapies, 10/2023 |
Dhakal, Binod, NK cell-based CAR and bispecific antibodies, Immune Effector Cell Therapy meeting by the International Myeloma Society, Boston, MA, 03/2024 |
Dhakal, Binod, Advances in stem cell transplantation and cellular therapy, Symposium, University of Kansas, 04/2024 |
Regional |
Dhakal, Binod, A man with cavitary lesion, Clinicopathological Conference, Saint Francis hospital, Evanston, IL, 11/2011 |
Dhakal, Binod, Smoldering Multiple Myeloma: Treat or Not to Treat?, The Chicago Multiple Myeloma Tumor Board, Chicago, IL, 08/2018 |
Dhakal, Binod, Current state of MRD in Multiple Myeloma, The Chicago Multiple Myeloma Tumor Board, Chicago, IL, 02/2019 |
Dhakal, Binod, Immunotherapy in Myeloma: Promise and Challenges, Grand Rounds Loyola University, Maywood, IL, 07/19/2019 |
Dhakal, Binod, Treating Multiple Myeloma during the COVID19 Pandemic, The Chicago Multiple Myeloma Tumor Board, Chicago, IL, 11/2020 |
Dhakal, Binod, Current Status and Future Applications of CAR-T cells in Multiple Myeloma, The Chicago Multiple Myeloma Tumor Board, Chicago, IL, 06/2021 |
Dhakal, Binod, Immunotherapy in Myeloma: Beyond CAR-T, 2nd Midwest Cellular Conference, 05/2022 |
Dhakal, Binod, The odd pair of paraproteinemia and neuropathy, The Chicago Multiple Myeloma Tumor Board, Chicago, IL, 09/2022 |
Local |
Dhakal, Binod, HIT and HITT: Diagnosis and Challenges, Invited Faculty Lecture; General Internal Medicine, Medical College of Wisconsin, 10/2011 |
Dhakal, Binod, Diagnostic gestalt in Pulmonary embolism, Invited Faculty Lecture; General Internal Medicine, Medical College of Wisconsin, 10/2012 |
Dhakal, Binod, Treatment Options of Relapsed/Refractory Multiple myeloma, 6th Annual Controversies in Hematological Malignancies Symposium, 03/2017 |
Dhakal, Binod, Autologous Stem Cell Transplantation in Multiple Myeloma, First Annual Multiple Myeloma Patient and Caregiver Symposium, 11/2017 |
Dhakal, Binod, Autologous Stem Cell Transplantation in Multiple Myeloma: Early or Late- the debate, 7th Annual Controversies in Hematological Symposium, 03/2018 |
Dhakal, Binod, How "significant" is Monoclonal Gammopathy of Undetermined Significance?, Grand Rounds, Division of Endocrinology, Medical College of Wisconsin, 06/13/2019 |
Dhakal, Binod, "Immunotherapy in Myeloma: Promise and Challenges. Development and Disease Therapeutics, Cancer Center, Medical College of Wisconsin, 09/2021 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
International |
Dhakal B., Eastwood D, Dhakal A, Santana-Davila R, 0 d post-op mortality and length of stay in obese patients after lung cancer surgery, Chest, 10/2013 |
Dhakal A., Pathak LK, Dhakal B., Eicu- is it effective?, Chest, 10/2013 |
Dhakal B., Cohen E, Palmer J, Hari P, Chronic-graft-versus-host disease presenting as Nephrotic syndrome, BMT tandem meetings, Grapevine, 02/2014 |
Hari P, Dhakal B, Thompson R, Hamadani M, Pasquini M, Chhabra S et al., Pharmacokinetics (PK) of Propylene Glycol-Free Melphalan HCl (PG-free MEL) in Multiple Myeloma (MM) Patients Undergoing Autologous Transplantation (AHCT), European Hematology Association Meeting, 2017 |
National |
Dhakal B., Chunzhi X, Zhong X, Hari P et al, Plerixafor overcomes the adverse effect of diabetes on hematopoietic progenitor cell mobilization, BMT tandem meeting, Salt Lake City, UT, 2013 |
Dhakal B., Strouse C, Arce-Lara C, D’Souza A, Esselman J, Pasquini M, Saber W, Drobyski W, Hari P, Hamadani M, American Society of Clinical Oncology, 06/2014 |
Dhakal B., Martens M, Kapke J, D'Souza A, Pasquini M, Saber W, Hamadani M, Drobyski W, Rizzo D, Horowitz M, Zhang M, Hari P, Outcomes of allogeneic hemaotpoietic cell transplantation for multiple myeloma: impact of disease risk and conditioning regimen, BMT Tandem Meetings, San Diego, CA, 02/2015 |
Dhakal B., Brazauskas R, Arce-Lara C, Pasquini M, Hari P, D'Souza A., Monocyte Recovery at Day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation, BMT Tandem Meetings, San Diego, CA, 02/2015 |
Westfall Veltri L, Dhakal B., Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini M, Fenske T, Hari P, Hamadani M, Kanate A, Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies, American Society of Clinical Oncology, 06/2015 |
Dhakal B., Ramalingam S, Shuff J, Epperla N, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D’Souza A, Atallah E, Erickson B, Fenske T, Hamadani M, Local control of ocular adnexal lympho-proliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies, American Society of Hematology, Orlando, FL, 12/2015 |
Dhakal B, Wang T, Haagenson M, Taylor C, Zhu F, Spellman S, Verneris M, Hsu K, Fleischhauer K, Lee S, Saber W, Pilot Study of Prognostic Impact of Pre-Allogeneic Hematopoietic Cell Transplantation Plasma Levels of CXC- chemokines (CXCL4 and CXCL7) in patients with Myelodysplastic Syndrome, American Society of Hematology, San Diego, CA, 12/2016 |
Dhakal B, Nelson A, Subramaniam G, Fraser R, Eastwood D, D’Souza A, Hari P, Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: Impact of Age, American Society of Hematology, San Diego, CA, 12/2016 |
Levin A, Kleman A, Tarima S, Michaelis L, Carlson K, Hamadani M, Fenske T, Hari P, Atallah E and Dhakal B, Early Mortality in Patients with Acute Promyelocytic Leukemia, American Society of Hematology, San Diego, CA, 12/2016 |
Subramaniam G, Dhakal B, Bhatt V, Mehta P, Foy P, Michaelis L, Carlson K and Atallah E, Incidence and Overall Survival of Therapy Related Myeloid Neoplasms in United States, American Society of Hematology, San Diego, CA, 12/2016 |
Dhakal B, Hari P, Rein L, Fraser R and Padmanabhan A, se of “Big Data” to Define Disease Burden, Complication Rates and Health Care Costs in Patients with Heparin Induced Thrombocytopenia (HIT), American Society of Hematology, San Diego, CA, 12/2016 |
Padmanabhan A, Curtis J, Pechauer S, Curtis D, Bougie D, Sullivan M, Irani M, Dhakal B, Baumann L, Pierce B and Aster R, A novel PF4-dependent P-Selectin Expression assay (PEA) facilitates early HIT antibodies: Implications for diagnosis and treatment of HIT, American Society of Hematology, San Diego, CA, 12/2016 |
Padmanabhan A, Curtis J, Pechauer S, Curtis B, Bougie D, Irani M, Bryant B, Alpenin B, Dhakal B, Wen R, Wang D and Aster R, Intravenous Immunoglobulin for treatment of severe refractory Heparin-induced thrombocytopenia, American Society of Hematology, San Diego, CA, 12/2016 |
Badros A, Zeba S, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M and Hari P, Marizomib for CNS-multiple myeloma, American Society of Hematology, San Diego, CA, 12/2016 |
Dhakal B, Egger L, Benoy G, Fredrich P, Jefcik S, Hari P, Margolis D, Taylor C, Punzalan R and Padmanabhan A, Tailoring” Hematopoietic Progenitor Cell Collection: Impact of a data-driven prediction algorithm for blood volume processing in large volume leukapheresis, American Society of Hematology, San Diego, CA, 12/2016 |
Dhakal B, Narra R, Smunt T, Canadeo A, Chhabra, S, D’ Souza A, Gyawali B, Hari P, Niraula S, Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs), American Society of Hematology, 2017 |
Dhakal B, Qi X, Subramaniam G, Narra R, Szabo A, Chhabra S, D’Souza A, Hari P, Using “Big-Data” to Evaluate in-Hospital Morbidity and Mortality in Systemic Light Chain (AL) Amyloidosis after High Dose Therapy and Autologous Stem Cell Transplant (HDT/ASCT), American Society of Hematology, 2017 |
Pagenkopf A, Dhakal B, Hope C, Papadas A, Johnson M, Nagel B, Kurudza E, Partha S, Ruffolo B, Leith C, Miyamoto S, Hematti P, Hari P, Callander N and Asimakopoulos F, Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT), American Society of Hematology, 2017 |
Subramanian G, Narra R, Dhakal B, Hamadani M, Michaelis L, Atallah E, Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States, American Society of Hematology, 2017 |
Patel G, Hari P, Szabo A, Lisa R, Baumann L, Chhabra S, Dhakal B, Anita D'Souza A, Acquired Factor X Deficiency in Light Chain (AL) Amyloidosis Is Rare and Associated with Advanced Disease, American Society of Hematology, 2017 |
Dhakal B, Chhabra S, Hamadani M, D’Souza A, Usmani S, Jackson J, Pasquini M and Hari P, Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials, American Society of Clinical Oncology, 2017 |
Pawarode A, D'Souza A, Pasquini M, Johnson B, Braun T, Dhakal B, Hamadani M, Magenau J, Shah N, Riwes M, Parkin B, Reddy P, Hari P, Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients, American Society of Hematology, 2017 |
Chhabra, S, Hari P, Visotcky A, Shah N, Rizzo D, Saber W, D'Souza A, Dhakal B, Anshu A, Thompson R, Fenske T, Shaw B, Drobyski W, Pasquini M and Hamadani M, Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study, American Society of Hematology, 2017 |
Subramanian G, Narra R, Dhakal B, Hamadani M, Michaelis L, Atallah E, Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States, American Society of Hematology, 2017 |
Dhakal B, D’Souza A, Hamadani M, Arce-Lara C, Schroeder K, Gauger K, Crone K, Pasquini M, Chhabra S and Hari P, Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results, American Society of Clinical Oncology, 2017 |
Dhakal B, Lisa R, Szabo A, Aster R, Padmanabhan A, Use of Intravenous Immunoglobulin G in HIT: Impact on Thrombosis and Mortality in a Population-Based Study, American Society of Hematology, 2018 |
Knight J, Rizzo D, Hari P, Kerswill S, D’Souza A, Logan B, Hamadani M, Chhabra S, Dhakal B, Shah N, Cole S, Propranolol inhibits stress-related gene expression profiles associated with adverse clinical outcomes in autologous hematopoietic cell transplantation recipients, BMT Tandem, 2018 |
Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah N, Gauger K, Keaton T, Pasquini M, Hari, P, Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM), American Society of Hematology, 2018 |
Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M, Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US, American Society of Hematology, 2018 |
Badar T, Hari P, Chhabra S, Dhakal B, Drobyski W, Fenske T, Hamadani M, Horowitz M, Pasquini M, Rizzo D, Saber W, Shah N, Shaw B, D’Souza A, Use of Propylene Glycol-Free Melphalan Conditioning in Light Chain Amyloidosis Patients Undergoing Autologous Hematopoietic Cell Transplantation is Associated with Significantly Lower Hospitalization Days, BMT Tandem, 2018 |
Dhakal B, Giri S, Levin A, Lisa R, Fenske T, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M, Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US, American Society of Hematology, 2018 |
Chhabra S, Narra R, Dhakal B, Jerkin J, Vazirabad J, Mehra V, Nytes J, Anderson M, Hari P, Sequence level comparison of unrelated allogeneic hematopoietic cell transplantation (allo-HCT) donor-recipient pairs: clinical outcome of allo-HCT pairs with no exonic sequence differences in the HLA-loci, BMT Tandem, 2018 |
D'Souza A, Flynn K, Dhakal B, Chhabra S, Pasquini M, Hari P, cycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study, American Society of Hematology, 2018 |
Costa LJ, Chhabra S, Godby Kelly, Medvedova E, Cornell F, Hall A, Silberman R, Innis-Shelton R, Dhakal B, Deldiaquez L, Harwick P, Biru Y, Omel J, Hari P, Callander N, Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Measurable Residual Disease (MRD)-Based, Response-Adapted Dara-KRd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM) MASTER trial, ASH, 2019 |
Hari P, Susanne Lentzsch S, Siegel D, Usmani S, Dhakal B, Rossi A, Rosenbaum C, Leng S, Divaya Bhutani D, Bhutani M, Biran N, Vesole D, Stork-Sloots L, de Snoo F, Dumee B, H. van Vliet M, Niesvizky R, Comparison of Riss and IMWG Risk Stratification Guidelines with Gene Expression Profile SKY92 in Newly Diagnosed Multiple Myeloma Patients; Results from the Prommis Trial, ASCO, 2019 |
Chhabra S, Hari, Visotcky A, Zhu F, Shah N, Rizzo D,Saber W, D’Souza A, Dhakal B, Abedin S, Runaas L, Cantrall K, Fenske T, Horowitz M, Shaw B, Drobyski W, Pasquini M, Hamadani M, A Phase I/2 Study of Ixazomib for chronic Graft-Versus-Host Disease (cGVHD) prophylaxis after allogeneic transplantation (alloHCT), Transplant and Cellular Therapy Meeting, 2019 |
Kleman A, Leng S, Szabo A, Wu R, Chhabra S, Dhakal B, Parameswaran H, Mueller C, Bhutani D, Sharma M, Lentzsch S, D'Souza A, Changes in cardiac biomarkers with daratumumab therapy in patients with light chain amyloidosis, IMS, 2019 |
Shelton L, Khan M, Hari P, Dhakal B, Cornell F, KD-PACE salvage therapy for aggressive relapsed multiple myeloma, IMS, 2019 |
Hari P, Susanne Lentzsch S, Siegel D, Usmani S, Dhakal B, Rossi A, Rosenbaum C, Leng S, Divaya Bhutani D, Bhutani M, Biran N, Vesole D, Stork-Sloots L, de Snoo F, Dumee B, H. van Vliet M, Niesvizky R, Comparison of Riss and IMWG Risk Stratification Guidelines with Gene Expression Profile SKY92 in Newly Diagnosed Multiple Myeloma Patients; Results from the Prommis Trial, EHA, 2019 |
Gowda L, Patel S, Girnius S, Dhakal B, Qaziblash M, Shah N, Kumar S, Davila O, Fraser R, Hari P, D’Souza A, Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation, ASH, 2019 |
Dhakal B, Fraser R, Gahvari Z, Hall A, Callander N, Chhabra S, Kumar S, Shah N, Qaziblash M, D’Souza A, Hari P, Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM), ASH, 2019 |
Thapa B, Dong Huaying, Tarima S, Dhakal B, Budesonide Prophylaxis Reduces Engraftment Syndrome (ES) after Autologous Hematopoietic Cell Transplantation (autoHCT) in Multiple Myeloma (MM), ASH, 2020 |
Dhakal B, Felizardo T, Lum L, D’Souza A, Chhabra S, Keaton T, Mohan M, Park J, Fowler D, Hari P, Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM), ASH, 2021 |
Dytfeld D, Dhakal B, Agha M, Manier S, Delforge M, Kuppens S, Afifi S, Deraedt W, Taraseviciute-Morris A, Sechter J, Gilbert J, Yalniz F, Florendo E, Pacaud L, Hungria V, Usmani S, Mateos M, Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5), ASH, 2021 |
Dhakal B, Einsele H, Schecter J, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Voelker J, Cost P, Valluri S, Florendo E, Pacaud L, Yong K, Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials, ASH, 2022 |
Dhakal B,Berdeja J,Gregory T, Ly T, Bickers C, Zong X, Wong L, Goodridge J, Cooley S, Valamehr B, Chu W, Byon J, Abonour R, Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with RRMM- very early data of NK CAR in MM, ASH, 2022 |
Hammons L, Haider S, Pasquini M, Chhabra S, Radhakrishnan S, Zamora A, Mohan M, Dong J, Janz S, D'Souza A, Hari P, Dhakal B, Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in RRMM), ASH, 2022 |
Costa L, Chhabra S, Medvedova E, Schmidt T, Dholaria B, Godby K,Silbermann R, Bal S, D'Souza A, Giri S, Omel J, Hari P, Callander N and Dhakal B, Outcomes of MRD-Adapted Treatment Modulation in Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: MASTER follow up, ASH, 2022 |
Quach H, Rajagopal R, Spencer A, Low M, Kazandjian D, Crescenzo R, Du C, Patel S, Mundra V, Cheng H and Dhakal B, Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t (11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study - novel bcl-2 in 11;14, ASH, 2022 |
Neupane N, Srivastava A, Sanjeevi A, Agrawal S, Mahmoud A, Shah A, Budhathoki P, Kharel H, Joshi U and Dhakal B, Racial Disparities in Hospital Outcomes of Autologous Stem Cell Transplantation for Multiple Myeloma: A Comparative NIS 2016 to 2020 Database Study, ASH, 2023 |
Biran N, Dhakal B, Niesvizky R, Lentzsch S, McKay J, Vesole D, Nooka A, Paul B, Hari P, Sork-Sloots L, D’Amboise S, Kuiper R, Vilet M, Siegel D, Usmani S, van Rhee F, Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival, 2023 |
Frigault M, Rosenblatt J, Dhakal B, Raje N,Cook D,Gaballa M, Emmanuel-Alejandro E, Nissen D, Banerjee K, Rotte A, Heery C, Avigan D, Jakubowiak A, Bishop M, Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients, ASH, 2023 |
Quach H, Sborov D, Kazandjian D, Spencer A, Low M, Bal S, Callander N, Cheng H, Patel S, Crescenzo R, Agarwal A, Dhakal B, Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t (11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose, ASH, 2023 |
Biran N, Dhakal B, Niesvizky R, Lentzsch S, McKay J, Vesole D, Nooka A, Paul B, Hari P, Sork-Sloots L, D’Amboise S, Kuiper R, Vilet M, Siegel D, Usmani S, van Rhee F, Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients, ASH, 2023 |
Sidiqi M, Corradini P, Purtill D, Einsele H, Dhakal B, Karlin L, Salomon Manier S, Iida S, Giebe S,Harrison S, Lipe B, Khan A, Schecter J,Jackson C,Yeh T, Banerjee A, Deraedt W, Lendvai N, Lonardi C,Slaughter A, Li K, Chen D, Gilbert J, Roccia T, Zhao M, Patel N, Florendo E, Koneru M, Costa Filho O, Geng D, San Miguel J and Yong K, Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4, ASH, 2023 |
Magnusson T, Costa L, Giri S, Ravi G, Godby K, Dhakal B, Dholaria B, Medvedova E, Callander N, Steele J, Langley K, Mullinax B, Sentell M, Horn S, Hill C, Boullion M and Bal S, Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed by Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy, ASH, 2023 |
Patwari A, Patel T, Bachu R, Esselmann J, Rein L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Al Hadidi A, Radhakrishnan S,Thanendrarajan S, Zangari M, van Rhee F, Dhakal B, D'Souza A,Mohan M Schinke C, The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T in Multiple Myeloma, ASH, 2023 |
Mohan M, Shah N,Luan D, Monge J, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M,Al Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C,Chakraborty R, Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study, ASH, 2023 |
Lin M, Szabo A, Pezzin L, Dong J, Dhakal B, Mohan M, Narra R, Pasquini M and D'Souza A, Does Socioeconomic Status Have an Impact on Light Chain (AL) Amyloidosis Disease Characteristics and Outcomes?, ASH, 2023 |
Kazandjian D, Quach H, Sia H, Joy Ho P, Spencer A, Mark A. Schroeder M Dhakal B,Cochrane T, Zonder J, Nancy J,Duchesne D, Shah T,Garton A, Menon V, Gn S, Sammicheli S, Zhukovsky E, Cyril Konto, Pacaud L and Tan P, Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM), ASH, 2023 |
Dhakal B, Mohan M, Narra R, Palen K, Szabo A, Kearl T, Ravi G, Bal S, Johnson J, Pasquini M, D’Souza A, Hari P, Costa L, Dual Targeting of SLAMF-7 and CD38 in Multiple Myeloma (MM): Ph2 Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in RRMM, ASH, 2023 |
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson Jr. A, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M, Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma, ASH, 2023 |
Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, San-Miguel, Einsele H, Phase 3 Results from Cartitude-4: Cilta-Cel versus standard of care in lenalidomide refractory multiple myeloma, ASCO, 2023 |
Neupane N, Srivastava A, Agrawal S, Shah A, Budhathoki P, Mahmoud A, Sanjeevi A, Kharel H, Joshi U and Dhakal B, Outcomes of Multiple Myeloma Hospitalization Undergoing Autologous Stem Cell Transplantation with and without CKD: A NIS 2016 to 2020 Database Study, ASH, 2023 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
08/2016 - 2021 Chair, Multiple Myeloma Tumor Board, Hematology and Oncology, Medicine, Medical College of Wisconsin |
08/2016 - Present Member, Chicago Multiple Myeloma Tumor Board Planning Committee, Hematology and Oncology, Medicine, Medical College of Wisconsin |
12/2021 - Present Vice Chair, DOT, BMT and CT, Hematology and Oncology, Medicine, Medical College of Wisconsin |
03/2023 - Present Member, DSMC Cancer Center, Hematology and Oncology, Medicine, Medical College of Wisconsin |
Hospital |
09/2013 - 2016 Member, Inpatient service committee, Froedtert and Medical College of Wisconsin |
04/2018 - Present Co-Chair, Outpatient BMT Operational Committee, Froedtert and Medical College of Wisconsin |
09/2018 - Present Member, CRS/CRES Working Committee for CAR-T, Froedtert and Medical College of Wisconsin |
MCW TEACHING ACTIVITIES: |
Medical Student Education |
07/2010 - 06/2013 Inpatient Teaching rounds for M3 and M4 |
07/2016 - Present Teaching Blood and Marrow Acting Internship |
07/2017 - 08/2017 Apprenticeship in Medicine |
Resident and Fellow Education |
07/2010 - 06/2013 Teaching rounds during inpatient rotation |
07/2016 - Present BMT 101 every year for incoming fellows |
07/2016 - Present Multiple Myeloma Lectures |
07/2016 - Present Teaching rounds inpatient and outpatient rotation |
11/2016 - Present Hematology Board Review Course |
03/2017 - Present Resident Academic Half Day (Myeloma 101) |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Medical Students |
06/2012 - 07/2012 Michael Sung, Mentor for M2 inpatient clinical rotation, Medical College of Wisconsin |
10/2017 - Present Sophie Miller, M3, Research Mentor, Medical College of Wisconsin |
08/2018 - Present Lin Gloria, Research Mentor, Medical College of Wisconsin |
Residents |
11/2013 - 06/2014 Christopher Strouse, Amyloidosis project, Medical College of Wisconsin |
11/2013 - 02/2015 Jonathan Kapke, Multiple myeloma project, Medical College of Wisconsin |
07/2014 - 06/2015 Arun Singavi, Lymphoma and Platelet refractory antibody project, Medical College of Wisconsin |
08/2014 - 04/2015 Ariel Nelson, Multiple myeloma project, Medical College of Wisconsin |
12/2014 - 2019 Nicholas Torgerson, Multiple Myeloma Project, Medical College of Wisconsin |
01/2015 - 2019 Ariel Kleman, Multiple myeloma and Benign Hematology project, Medical College of Wisconsin |
01/2015 - 2019 Adam Levine, Multiple Myeloma and hematological malignancies, Medical College of Wisconsin |
04/2015 - 04/2016 Sridevi Ramalingam, Lymphoma and Platelet refractory antibody project, Medical College of Wisconsin |
12/2022 - Present Shabi Haider, Multiple Myeloma Project, Medical College of Wisconsin |
06/2023 - Present Hayley Vandenboom, Multiple Myeloma Project, Medical College of Wisconsin |
Faculty |
06/2016 - Present Guru Subramaniam, Research and MS Thesis Mentor, Medical College of Wisconsin |
07/2017 - Present Ravi Narra, Research and MS Thesis Mentor, Medical College of Wisconsin |
01/2018 - Present Smith Giri, Multiple Myeloma, Medical College of Wisconsin |
06/2018 - Present Madan Aryal, Multiple Myeloma, Medical College of Wisconsin |
07/2020 - Present Gulrayz Ahmed, Multiple Myeloma, Medical College of Wisconsin |
07/2020 - Present Bicky Thapa, Multiple Myeloma, Medical College of Wisconsin |
07/2021 - Present Lindsay Hammons, Multiple Myeloma, Medical College of Wisconsin |
08/2022 - Present Ramsha Ahmed, Multiple Myeloma, Medical College of Wisconsin |
12/2022 - Present Jennifer Obasi, Multiple Myeloma, Medical College of Wisconsin |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024 Mar 06;14(1):38. PMCID: PMC10915134 |
2. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):373-379. |
3. Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May;59(5):647-652. |
4. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar;204(3):887-891. |
5. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 Mar;30(3):285-297. |
6. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, Leleu X, Avivi I, Cavo M, Ishida T, Kim SJ, Roeloffzen W, van de Donk NWCJ, Dytfeld D, Sidana S, Costa LJ, Oriol A, Popat R, Khan AM, Cohen YC, Ho PJ, Griffin J, Lendvai N, Lonardi C, Slaughter A, Schecter JM, Jackson CC, Connors K, Li K, Zudaire E, Chen D, Gilbert J, Yeh TM, Nagle S, Florendo E, Pacaud L, Patel N, Harrison SJ, Einsele H. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023 Jul 27;389(4):335-347. |
7. Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J. Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance. Leukemia. 2024 Feb;38(2):383-385. PMCID: PMC11326531 |
8. Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023 Oct;29(10):594-597. |
9. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023 Nov;10(11):e890-e901. PMCID: PMC10836587 |
10. Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood Adv. 2023 Sep 26;7(18):5549-5553. PMCID: PMC10514068 |
11. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar 01;109(3):906-914. PMCID: PMC10905074 |
12. Silbermann RW, Schmidt TM, Bal S, Dhakal B, Dholaria B, Biltibo E, Chhabra S, Giri S, Godby KN, Gowda S, Medvedova E, Cornell RF, Callander NS, Costa LJ. Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation. EJHaem. 2023 Aug;4(3):775-778. PMCID: PMC10435700 |
13. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Jul 15;129(14):2179-2191. PMCID: PMC10516285 |
14. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 Dec 01;29(23):4784-4796. PMCID: PMC10690096 |
15. Wu JF, Dhakal B. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting. J Hematol Oncol. 2023 Jul 28;16(1):86. PMCID: PMC10385907 |
16. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 Apr;58(4):443-445. |
17. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. |
18. Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 Aug 01;108(8):2249-2254. PMCID: PMC10388259 |
19. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplant Cell Ther. 2022 Jun;28(6):284-293. |
20. Hodge A, Sheean P, O'Connor P, Tyler K, Kerschner A, Williams A, Jensik K, Visotcky A, D'Souza A, Hari P, Dhakal B, Chhabra S, Flynn KE, Hagen P, Stolley M. Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. Support Care Cancer. 2022 Dec;30(12):9771-9779. |
21. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717. |
22. Hammons LR, Szabo A, Janardan A, Dhakal B, Chhabra S, D'Souza A, Mohan M. Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma. JAMA Netw Open. 2022 Oct 03;5(10):e2238961. PMCID: PMC9617177 |
23. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 Dec;97(12):E451-E453. |
24. Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, Chhabra S, Medvedova E, Godby KN, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS, Costa LJ. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. Am J Hematol. 2022 Sep;97(9):1170-1177. |
25. Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022 Sep 01;40(25):2901-2912. |
26. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):863-868. |
27. Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. 2022 May 25;12(5):82. PMCID: PMC9132975 |
28. Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr., Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 Jul 12;6(13):3991-3995. PMCID: PMC9278304 |
29. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 Jul;97(7):E276-E280. PMCID: PMC10476149 |
30. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale J Biol Med. 2022 Mar;95(1):45-56. PMCID: PMC8961707 |
31. Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P. Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J. 2022 Feb 24;12(2):34. PMCID: PMC8873507 |
32. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022 Apr 11;40(4):340-342. PMCID: PMC8864440 |
33. Dhakal B, Sharma S, Balcioglu M, Shchegrova S, Malhotra M, Zimmermann B, Billings PR, Harrington A, Sethi H, Aleshin A, Hari PN. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front Oncol. 2022;12:786451. PMCID: PMC8848740 |
34. Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS. Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497. PMCID: PMC8767926 |
35. Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Mol Cancer Ther. 2022 Apr 01;21(4):502-510. PMCID: PMC8983490 |
36. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022 Feb;28(2):83.e1-83.e9. PMCID: PMC8900987 |
37. Dhakal B, Chhabra S, Savani BN, Hamadani M. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. Br J Haematol. 2022 Apr;197(1):28-40. |
38. Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells. 2021 Aug 02;10(8). PMCID: PMC8391934 |
39. Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021 Oct 07;138(14):1278-1281. PMCID: PMC8332674 |
40. Mohan M, Hari P, Szabo A, Dhakal B, Chhabra S, D'Souza A. Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leuk Res. 2021 Oct;109:106648. |
41. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021;12:667054. PMCID: PMC8206561 |
42. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun;35(6):1828. PMCID: PMC8188513 |
43. Mohan M, Hari P, Dhakal B. Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. JCO Oncol Pract. 2021 Jul;17(7):405-413. |
44. Alsouqi A, Khan M, Dhakal B, Du L, Harrell S, Hari P, Cornell RF. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):526-535. |
45. Biran N, Dhakal B, Lentzsch S, Siegel D, Usmani SZ, Rossi A, Rosenbaum C, Bhutani D, Vesole DH, Rodriguez C, Nooka AK, van Rhee F, Stork-Sloots L, de Snoo F, Bhattacharyya PK, Dash DP, Zümrütçü S, van Vliet MH, Hari P, Niesvizky R. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021 Aug;2(3):375-384. PMCID: PMC9175784 |
46. Giri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis Journal of Geriatric Oncology. November 2020;11(8):1285-1292. |
47. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 Nov;191(3):442-452. PMCID: PMC7990054 |
48. Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M. Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. Biol Blood Marrow Transplant. 2020 Nov;26(11):2011-2017. |
49. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859 |
50. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021 Jan 01;127(1):82-92. PMCID: PMC7736245 |
51. Dhakal B, Wang T, Kuxhausen M, Zhu F, Taylor C, Spellman SR, Verneris MR, Hsu K, Fleischhauer K, Lee SJ, Bolon YT, Carlson KS, Nazha A, Saber W. Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021 Jan;62(1):229-233. PMCID: PMC7939047 |
52. Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 2020 Dec;26(12):2229-2236. |
53. Dhakal B, D'Souza A, Kleman A, Chhabra S, Mohan M, Hari P. Salvage second transplantation in relapsed multiple myeloma. Leukemia. 2021 Apr;35(4):1214-1217. PMCID: PMC8020391 |
54. Dhakal B, D'Souza A, Chhabra S, Hari P. Multiple myeloma and COVID-19. Leukemia. 2020 Jul;34(7):1961-1963. |
55. Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Jan;56(1):225-231. PMCID: PMC7855279 |
56. Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood Marrow Transplant. 2020 Jul;26(7):1288-1297. |
57. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer. 2020 Jun 15;126(12):2791-2801. |
58. D'Souza A, Szabo A, Flynn KE, Dhakal B, Chhabra S, Pasquini MC, Weihrauch D, Hari PN. Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial EClinicalMedicine. June 2020;23. |
59. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug;35(4):307-315. |
60. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 May;26(5):893-901. |
61. Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020 May;41:100643. |
62. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 Dec;34(12):3338-3347. PMCID: PMC7572530 |
63. Dhakal B, Rein L, Szabo A, Padmanabhan A. Use of IV Immunoglobulin G in Heparin-Induced Thrombocytopenia Patients Is Not Associated With Increased Rates of Thrombosis: A Population-Based Study. Chest. 2020 Sep;158(3):1172-1175. PMCID: PMC7478227 |
64. Bhasin B, Szabo A, Wu R, Saad ER, Hari P, Dhakal B, Chhabra S, D'Souza A. Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e468-e473. PMCID: PMC7450520 |
65. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267 |
66. Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. J Clin Apher. 2019 Dec;34(6):686-691. PMCID: PMC6957224 |
67. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. PMCID: PMC6663939 |
68. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec;26(4):210-215. |
69. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476. |
70. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M, OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):781-794. |
71. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497. |
72. Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):10-14. |
73. Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019 Oct;60(10):2558-2562. PMCID: PMC7176050 |
74. Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e251-e258. |
75. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. PMCID: PMC6453717 |
76. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. |
77. Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW. Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. Biol Blood Marrow Transplant. 2019 May;25(5):921-931. |
78. Bhandari S, Pandey RK, Dahal S, Shahreyar M, Dhakal B, Jha P, Venkatesan T, Saeian K. Risk, Outcomes, and Predictors of <i>Clostridium difficile</i> Infection in Lymphoma: A Nationwide Study. South Med J. 2018 Oct;111(10):628-633. |
79. Dhakal B, Szabo A, Hari P. Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma-Reply. JAMA Oncol. 2018 Nov 01;4(11):1618. |
80. Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma. Transl Res. 2018 Nov;201:49-59. |
81. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018 Aug;71:95-99. |
82. Podder V, Dhakal B, Shaik GUS, Sundar K, Sivapuram MS, Chattu VK, Biswas R. Developing a Case-Based Blended Learning Ecosystem to Optimize Precision Medicine: Reducing Overdiagnosis and Overtreatment. Healthcare (Basel). 2018 Jul 10;6(3). PMCID: PMC6163835 |
83. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588 |
84. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Aug;24(8):1610-1614. |
85. Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol. 2018 May;5(5):e220-e231. PMCID: PMC6437775 |
86. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670. |
87. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213. |
88. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01;4(3):343-350. PMCID: PMC5885822 |
89. Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Dhakal B, Pierce B, Aster RH, Padmanabhan A. A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. Chest. 2017 Oct;152(4):e77-e80. PMCID: PMC5812761 |
90. Bhandari S, Mohammed Abdul MK, Dhakal B, Kreuziger LB, Saeian K, Stein D. Increased Rate of Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients with Clostridium Difficile Infection. Inflamm Bowel Dis. 2017 Oct;23(10):1847-1852. |
91. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. Am J Hematol. 2017 Sep;92(9):E563-E565. |
92. Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, Dhakal B, Wen R, Wang D, Aster RH. IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest. 2017 Sep;152(3):478-485. PMCID: PMC5812774 |
93. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017 Dec;8:33-38. PMCID: PMC5898504 |
94. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):305-311.e2. |
95. Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017 Apr;177(2):221-225. |
96. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172. |
97. Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P. Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. Case Rep Hematol. 2016;2016:2389038. PMCID: PMC5097796 |
98. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 Oct;22(10):1773-1780. |
99. Krishnan A, Vij R, Keller J, Dhakal B, Hari P. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. Am Soc Clin Oncol Educ Book. 2016;35:210-21. |
100. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86. |
101. Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ. DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. Case Rep Med. 2016;2016:8503275. PMCID: PMC4749780 |
102. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016 Apr;51(4):492-500. |
103. Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Research. 2016;5. |
104. Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 Feb;51(2):297-9. PMCID: PMC4956087 |
105. Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant. 2016 Feb;51(2):300-2. |
106. Dhakal B, Harrington AM, Stadler ME, D'Souza A. Localized lymph node light chain amyloidosis. Case Rep Hematol. 2015;2015:816565. PMCID: PMC4398934 |
107. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015 Apr;50(4):610-2. |
108. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN. Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant. 2015 Mar;50(3):449-51. |
109. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31. |
110. Dhakal B, Giese K, Santo-Thomas L, Field JJ. Death during an asthma exacerbation in an adult with sickle cell disease: an autopsy case study. Am J Hematol. 2013 Sep;88(9):824. |
111. Dhakal B, Eastwood D, Sukumaran S, Hassler G, Tisol W, Gasparri M, Choong N, Santana-Davila R. Morbidities of lung cancer surgery in obese patients. J Thorac Cardiovasc Surg. 2013 Aug;146(2):379-84. PMCID: PMC4986510 |
112. Dhakal B, Singh V, Shrestha A, Rao A, Choong N. Pemetrexed induced pneumonitis. Clin Pract. 2011 Sep 28;1(4):e106. PMCID: PMC3981441 |
113. Biswas R, Dhakal B, Das RN, Shetty KJ. Resolving diagnostic uncertainty in initially poorly localizable fevers: a prospective study. Int J Clin Pract. 2004 Jan;58(1):26-8. |
114. Anderson LD Jr, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, Perales MA, Pasquini MC; CAR T-Cell therapy for Myeloma: Where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther 2023 Oct 30 |
115. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium; Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. Bone Marrow Transplant 2023 Oct 06 |
116. Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S; Ciltacabtagene Autoleucel in Patients with Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk 2023 Aug 22 |
117. Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, Htut M, Shah N, Wong SW, Sidana S, Cowan AJ, Alsina M, Cohen A, Holstein SA, Bergsagel L, Ailawadhi S, Raje N, Dhakal B, Rossi A, Lin Y; Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther 2023 Apr;29(4):255-258 |
118. Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P; Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv 2022 04 26;6(8):2466-2470
|
119. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M; Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021 10;21(10): e775-e781 |
120. Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, Hamadani M, Dhakal B, Usmani SZ. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024 Aug;30(8):750-759. |
121. Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 Apr 22;14(1):69. PMCID: PMC11035596 |
122. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 Aug 27;8(16):4320-4329. PMCID: PMC11372811 |
123. Hansen DK, Dhakal B, Hamadani M, Dingli D, Jain T, Huff CA, Janakiram M, Liu YH, De Braganca KC, Lodowski N, Sander J, Okorozo P, McFarland L, Perciavalle M, Huo S, Qureshi ZP, Patel KK. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. Front Immunol. 2024;15:1405452. PMCID: PMC11194690 |
124. Kim M, Arabi J, McCoy C, D'Souza A, Chhabra S, Abid MB, Thapa B, Dhakal B. Safety of Dapsone for Pneumocystis Jiroveci Pneumonia Prophylaxis in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):804-807. |
125. San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20(33):2509-2520. PMCID: PMC11537292 |
126. Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, He J, Kharat A, Cost P, Valluri S, Yong K. Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Adv. 2024 Oct 08;8(19):5062-5071. PMCID: PMC11459902 |
127. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood Cancer J. 2024 Aug 12;14(1):137. PMCID: PMC11319778 |
128. Schinke C, Dhakal B, Mazzoni S, Shenoy S, Scott SA, Richards T, Le HH, DeBrosse A, Okorozo P, McDowell R, Patel S, Bunn J, Hawks K, Zhang X, Rodriguez C. Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers. Curr Med Res Opin. 2024 Oct;40(10):1705-1711. |
129. Akhtar OS, Szabo A, Bhatlapenumarthi V, Forsberg M, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Patel T, Shrestha A, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, Shah MR, Bag A, D'Souza A, Schinke C, Chakraborty R, Shah N, Mohan M. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. Br J Haematol. 2024 Nov;205(5):1830-1834. |
130. Wu JF, Estrada-Merly N, Dhakal B, Mohan M, Narra RK, Pasquini MC, D'Souza A. Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center. Transplant Cell Ther. 2024 Dec;30(12):1189.e1-1189.e10. |
131. Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8. |
132. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan 02;145(1):85-97. |
133. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2024 Oct 01;30(19):4542. PMCID: PMC11443237 |
134. Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2024 Dec;205(6):2370-2375. |
135. Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B. Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. Eur J Cancer. 2025 Jan 17;215:115157. |
136. Narra RK, Peshin S, Dhakal B. Novel Approaches of Cellular Therapy in Multiple Myeloma - Focus on CART. Acta Haematol. 2024 Dec 28:1-25. |
137. Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD Jr, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study. Blood Adv. 2024 Dec 30. |
Books, Chapters, and Reviews |
1. Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Autonomic nervous system control of multiple myeloma. Blood Rev. 2021 Mar;46:100741. PMCID: PMC7876165 |
2. Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2021 Jan;56(1):9-19. |
3. Dhakal B, Janz S. Myeloma sleeper agent in myeloid disguise. Blood. 2019 Jul 04;134(1):3-4. |
4. Hari P, Dhakal B; Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Current Manual of Blood and Marrow Transplantation; Editors: Syed Abutalib and Parameswaran Hari © 2017 John Wiley & Sons 2017 |
5. Dhakal B., Vesole D., Hari P.: Allogeneic stem cell transplantation in multiple myeloma: Is there a future? Bone marrow transplantation, 2015 |
6. Dhakal B., Hari P: Statistics: Do we understand the results of our own analysis? Current Trends and Indications for Hematopoietic Cell Transplantation. In: Current Concepts and Controversies in Hematopoietic Cell Transplantation. Lazarus HM, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, Abutalib S. (editors). Cambridge University Press, Cambridge, UK, 2014. |
7. Dhakal B., Susan R.: Medical Student perspectives; Journey through different worlds. User Driven Health Care and Narrative Medicine, 2011 |
Non-Refereed Journal Publications/Original Papers |
1. Dhakal A., Dhakal B., Pathak L.K., Marina S., Vimala V.: eICU STUDY: A proof of concept. IJUDH 2(2): 1-5, 2014 Apr |
2. Biswas R., Dhakal B. et al.: Medical student narratives for understanding disease and social order in the third world. Eubios J of Int Bioethics 13:139-142, 2003 |
3. Biswas R., Dhakal B. et al.: Developing holistic care in the third world. Eubios J of Int Bioethics 12: 143-147, 2002 |
